FOR INVESTORS

Innovating Precision in Cosmetic Surgery

 

Executive Summary

 

Company: MagStone Ventures Inc.

 

Founder:Indrek Miidla MD FACS. Board-certified surgeon with extensive research and clinical expertise.  

 

Product: Smart Cannula® system – A revolutionary medical technology for liposuction and body contouring that combines real-time visualization in 2D and 3D, AI-driven treatment optimization, and safety mechanisms to enhance precision in cosmetic surgery.  Integration of the Smart Cannula® system with Bluetooth®. 

 

Mission: To redefine energy-based cosmetic treatments by merging surgical expertise with cutting-edge AI and sensor technology.  

 

Funding Goal: Raise $5-10 million via equity financing to finalize R&D, secure regulatory approvals, and launch production.  

 

Market Potential: Projected valuation of $150 million within 5 years, targeting the rapidly growing $18B+ global cosmetic surgery market.  

 

---

 

Company Overview

​

Background:

  

- Founded by a surgeon-researcher to address inefficiencies and risks in traditional liposuction and body contouring.  

- Combines clinical insights with advanced engineering to create safer, data-driven surgical tools.  

 

Core Innovations:  

​

1. Real-time Visualization: Tracks cannula movements via integrated sensors (magnetic/ultrasound) and displays them on-screen in 2D.  

2. AI-Powered Treatment Planning: Analyzes tissue data to recommend optimal energy delivery (RF, laser, ultrasound) and document outcomes.  Inegrated with Bluetooth®.

3. Safety Protocols: Automatically halts treatment if the cannula nears critical zones (e.g., skin surface).  

4. Multilevel Treatment & Plotter: Enables precise layered treatment and contour mapping in 3D for consistent results. 

5. Final goal is to integrate the Smart Cannula® system with robotically assisted treatment systems. 

 

IP (intellectual property) Portfolio:

 

- 5 pending U.S. patents.  

- Trademark secured for "Smart Cannula®" 

-We have currently developed  four working prototypes for different Smart Cannula® applications.

 

​

 

Market Analysis

​

Industry Trends:  

- **$18.3B global cosmetic surgery market** (2024), growing at 7.5% CAGR (compound annual growth rate), driven by demand for minimally invasive procedures. 

 

- Surgeons prioritize tools that reduce complications (e.g., burns, uneven results) and improve patient satisfaction.  

 

Target Customers:  

​

- Plastic surgeons, dermatologists, and med-spas specializing in body contouring.  

- Key markets: U.S., Europe, Asia-Pacific (South Korea, Brazil).  

 

Competitive Edge: 

 

- No direct competitors offer AI-guided, sensor-integrated cannulas with real-time feedback.  

- Indirect competitors (e.g., Cynosure, Solta Medical, InMode, Alma) focus on standalone energy devices without Smart Cannula’s precision or safety features.  

 

Validation:  

- Positive feedback from plastic surgeons and bio-engineers during preliminary market research.  

 

​

 

Product Development & Roadmap

​

Current Stage: Prototype development with sensor integration and AI algorithm testing. We have at this time four working prototypes for different applications and we are working constantly to improve the functionality of the system.

 

Milestones:  

1. Q1-2 2025: Finalize engineering and funding of the project.  

2. Q1-4 2025: Work on improvement of the products.  

3. Q3-4 2025: CE Marking (EU) and FDA 510(k) clearance.  

4. Q1-4 2026: Clinical trials and marketing.  

5. Q1 2027 Launch clinical products.

​

 

Revenue Model 

1. Device Sales: $80,000–$100,000 per unit (target: 200 units Year 1).  

2. Software Subscription: $2,000-3000/year for AI updates and data analytics.  

3. Consumables: Disposable sensors  ($200-300/procedure). 

4. Smart Cannulas® can be used multiple times after sterilization. 

 

Projected Revenue:  

​

- Year 1: $10-15M  

- Year 3: $50-75M (post-full market penetration).  

 

​

 

Funding Requirements

​

Seed Round: $5-10 million equity financing. After reaching planned milestones additional financing may be required before product can be fully launched.  

Use of Funds: 

 

- 30%: R&D (final prototyping, AI refinement).  

- 20%: Regulatory approvals and trials.  

- 30%: Engineering/software team expansion.  

- 10%: Marketing/IP legal costs.  

- 10%:Administrative cost

 

Exit Strategy:  

​

- Acquisition by major medtech firms (e.g., Medtronic, Stryker, InMode, Alma, Intuitive).  

- IPO after achieving scale.  

 

​

 

Team & Advisors 

Founder: Surgeon with 30+ years in  surgery and research.  

 

Advisors: 

 

- Biomedical engineers specializing in surgical robotics.  

- Regulatory expert with FDA clearance experience.  

- Plastic surgeons international and US 

-European project manager for CP mark and marketing

 

Recruitment:

Actively hiring AI developers and sensor engineers.  

 

​

 

Risk Mitigation

 

1. Regulatory Delays: Partner with regulatory consultants for streamlined approvals.  

2. Technical Hurdles: Allocate 20% of budget to contingency engineering.  

3. Market Adoption: Offer training programs and surgeon workshops.  

 

---

 

Financial Projections

- Pre-Money Valuation: $20M (based on IP and market potential).  

- Post-Money Valuation: $30M (post-$10M raise).  

- Projected ROI: 25x over 5 years (based on $250M exit).  

 

---

 

Conclusion 

MagStone Ventures bridges a critical gap in cosmetic surgery with its Smart Cannula®, offering unprecedented precision, safety, and AI-driven insights. With $5M in seed funding, the company will disrupt a multi-billion-dollar industry while delivering outsized returns to early investors.  

 

Appendices:  

- Patent filings.  

- Market research data.  

- Letters of intent from surgeons and industry specialists, bio-engineers.  

- Detailed financial model.